TRT, enclomiphene, and HCG monotherapy represent three distinct clinical approaches to testosterone optimization, each with different mechanisms, efficacy profiles, and fertility implications. TRT delivers the highest testosterone levels (700–1000+ ng/dL) but suppresses natural production, while enclomiphene raises T approximately 175% without shutdown, and HCG preserves both testicular function and fertility.
Low testosterone affects roughly 40% of men over 45. The clinical landscape now offers three validated approaches — each targeting the HPG axis differently, with different profiles for T-levels, fertility, cost, and reversibility.
Directly replaces testosterone via injection, gel, patch, or pellet. Bypasses the HPG axis entirely. Gold standard for maximum T-levels. Suppresses natural production.
Exogenous TestosteroneOral SERM that blocks estrogen receptors in the hypothalamus, stimulating LH and FSH. Body produces its own T. Preserves fertility and testicular function. No shutdown.
HPG Axis StimulationHuman chorionic gonadotropin acts as an LH analog, directly stimulating Leydig cells in the testes. Raises T while maintaining testicular volume, sperm production, and fertility.
LH MimeticComprehensive data across mechanism, efficacy, fertility impact, dosing, cost, reversibility, and ideal candidate profile.
| Parameter | 💉 TRT (Exogenous T) | 💊 Enclomiphene | 🧬 HCG Monotherapy |
|---|---|---|---|
| Mechanism | Exogenous testosterone replaces endogenous production; bypasses HPG axis | SERM blocks hypothalamic estrogen receptors → ↑LH + ↑FSH → endogenous T | LH analog directly stimulates Leydig cells in testes to produce testosterone |
| T Increase | 700–1,000+ ng/dL achievable (from typical 200–400 baseline) | ~175% above baseline in clinical trials (Wiehle et al., 2014) | Moderate increase — into normal range for most; 400–700 ng/dL typical |
| Fertility Impact | Suppresses fertility — shuts down LH/FSH via negative feedback; azoospermia common | Preserves/improves fertility — FSH maintained; spermatogenesis intact | Preserves fertility — maintains Leydig cell function and spermatogenesis |
| Administration | IM injection weekly or bi-weekly (cypionate/enanthate); or daily gel/cream | Oral tablet daily — 12.5–25 mg/day; no injections required | SubQ or IM injection 2–3× per week; more frequent than TRT |
| Injection Frequency | 1–2× per week (ester-dependent) | None — oral pill | 2–3× per week |
| Estimated Cost/Month | $30–$150 (generic cypionate); $300–$800 with brand-name formulations | $80–$200 (compounded); limited generic availability | $150–$400+ (compounded HCG); availability varies post-2020 FDA ruling |
| Reversibility | Partially reversible — recovery can take 6–18 months; some permanent suppression risk | Fully reversible — discontinue and HPG axis resumes; T returns to baseline | Fully reversible — discontinue; LH production resumes normally |
| HPG Axis Suppression | Yes — complete suppression of endogenous LH and FSH | No — stimulates axis; LH and FSH increase | Partial — exogenous LH signal; endogenous LH may decrease modestly |
| Testicular Atrophy | Yes — common without HCG; significant volume loss over months | No — volume maintained | No — volume preserved or improved |
| Common Side Effects | Erythrocytosis (elevated hematocrit), acne, oily skin, mood swings, testicular atrophy, estrogen elevation requiring AI | Visual disturbances (rare), mood changes (less than TRT), mild estrogen effects; generally well tolerated | Elevated estradiol (E2), acne, gynecomastia risk if E2 rises; generally mild |
| FDA Status | FDA-approved (testosterone cypionate, enanthate, gel formulations) | Off-label / investigational in US; Androxal (brand) lost approval pursuit; compounded widely | Compounded only (post-2020 FDA ruling removed brand Novarel/Pregnyl from compounding lists) |
| Best For | Severe hypogonadism, maximum T levels, men not concerned about fertility, athletes/bodybuilders | Mild-moderate hypogonadism, men wanting to preserve fertility, oral preference, natural axis support | Secondary hypogonadism with fertility goals, TRT adjunct (250–500 IU 2–3×/wk), testicular atrophy prevention |
Mechanism, dosing, clinical outcomes, and who it's actually best suited for.
TRT delivers exogenous testosterone directly into the body, bypassing the hypothalamic-pituitary-gonadal (HPG) axis entirely. It's the gold standard for raising testosterone to optimal levels — typically 700–1,000+ ng/dL on a 100–200 mg/week protocol. The primary drawback is HPG suppression: the hypothalamus detects elevated T, reduces GnRH, and the pituitary stops secreting LH and FSH. This shuts down endogenous testosterone production, sperm production, and causes testicular atrophy within weeks to months.
Enclomiphene is the trans-isomer of clomiphene citrate (Clomid), purified to remove the zuclomiphene isomer associated with visual side effects. It acts as a selective estrogen receptor modulator (SERM) at the hypothalamus, blocking the negative feedback signal that normally suppresses GnRH. This triggers increased LH and FSH secretion — stimulating the testes to produce more testosterone naturally. The result: T levels rise roughly 175% above baseline in clinical trials, with spermatogenesis and testicular volume preserved. For men with secondary hypogonadism who want to avoid the shutdown associated with TRT, enclomiphene is a compelling oral alternative. See the full Enclomiphene Research Guide for detailed data.
Human chorionic gonadotropin (hCG) is structurally similar to luteinizing hormone (LH) and binds the same LH receptor on Leydig cells in the testes. Unlike TRT which bypasses the testes, HCG directly stimulates them to produce testosterone — maintaining testicular volume, Leydig cell health, and sperm production. As monotherapy, HCG (1,500–3,000 IU administered 2–3× per week) raises testosterone into the normal range for most men with secondary hypogonadism. It's also used as a TRT adjunct at lower doses (250–500 IU) to preserve fertility in men already on testosterone. Availability has tightened since the 2020 FDA ruling removing compounded HCG from certain exemptions.
Work through the key questions. Each answer narrows the field. Discuss final decisions with a qualified hormone specialist.
Nothing achieves higher, more consistent T-levels than direct testosterone replacement. 100–200 mg/week of cypionate reliably produces 700–1,000+ ng/dL. If you need the absolute ceiling — severe hypogonadism, low T symptoms that haven't responded to other approaches — TRT is the gold standard.
TRT shuts down sperm production via HPG suppression. Both enclomiphene (maintains FSH/LH) and HCG (LH analog stimulating Leydig cells) preserve spermatogenesis. If conception is a near or mid-term goal, avoid exogenous testosterone without adding HCG.
Enclomiphene is the only oral option of the three. Daily tablet, no syringes, no reconstitution. For injection-averse patients or those wanting the simplest protocol, enclomiphene's compliance advantage is significant — especially when the T increase (175% above baseline) is sufficient for their needs.
HCG at 250–500 IU 2–3× per week alongside TRT restores testicular function and maintains sperm production. This is the standard protocol for TRT patients who want to conceive. Enclomiphene can also be substituted for HCG in TRT-combination protocols.
Want to try restoring natural production before committing to TRT? Enclomiphene is the strongest first option for secondary hypogonadism. It stimulates your body's own production without shutting down the axis — if it works well enough, you avoid the long-term commitment of exogenous testosterone entirely. If T levels are still insufficient after 3–6 months, transition to TRT remains easy since no axis damage has occurred.
Relative T optimization across protocols. Bars represent approximate achievable range normalized against a 400 ng/dL baseline. Based on published clinical data.
Relevant supplements and supplies for testosterone optimization protocols.
Affiliate links support MeetPeptide at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and informational purposes only. It does not constitute medical advice. Testosterone replacement therapy, enclomiphene, and HCG are prescription medications or compounded substances that require physician oversight. Exogenous testosterone is a controlled substance (Schedule III) in the United States. Enclomiphene is not FDA-approved in the US and is dispensed off-label via compounding pharmacies. HCG availability via compounding changed following the 2020 FDA ruling. Always consult a qualified healthcare provider or hormone specialist before starting, changing, or stopping any hormone therapy. Data cited is sourced from published peer-reviewed research; this page does not account for individual medical history, contraindications, or current drug interactions. Results vary significantly between individuals.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.